Emerging retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the weight loss community. Preliminary clinical trials have revealed impressive decreases in physical size and gains in metabolic markers for individuals with obesity . Researchers believe this unique approach